Compared to those receiving GLP‐1 RA therapy, patients who underwent BS had a significantly lower risk of HCC (HR, 0.304; 95% CI, 0.099–0.931), which showed the strongest protective effect, followed by a substantial reduction in NASH (HR, 0.509; 95% CI, 0.469–0.551). Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.